View Post

Pyrotinib Combo Improves PFS in HER2+ Metastatic Breast Cancer

In Clinical Studies News by Barbara Jacoby

By: Denise Myshko From: Pyrotinib plus capecitabine achieved a better progression-free survival (PFS) than lapatinib (Tykerb) plus capecitabine in patients with HER2-positive metastatic breast cancer (MBC) previously treated with trastuzumab and chemotherapy. Results from the phase 3 PHOEBE trial (NCT03080805) with were presented as part of the 2020 ASCO Virtual Scientific Program. The median PFS was 12.5 months (95% …